6 hours Ago By Defense World Staff
Amneal Pharmaceuticals ( NASDAQ:AMRX – Get Free Report ) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday. Other analysts have also issued reports about the company.
Truist Financial raised their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd.
Piper Sandler raised their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th.
Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price on the stock in a research report on Friday, September 6th.
One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.
00. Read Our Latest Research Report on Amneal Pharmaceuticals Amneal Pharmaceuticals Price Performance Insiders Place Their Bets In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the firm’s stock in a transaction that occurred on Friday, November 15th.
The shares were sold at an average price of $8.61, for a total value of $375,886.77.
Following the transaction, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This trade represents a 76.
16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Company insiders own 26.
56% of the company’s stock. Institutional Inflows and Outflows Large investors have recently made changes to their positions in the stock. Rubric Capital Management LP grew its stake in shares of Amneal Pharmaceuticals by 12.
4% during the second quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after purchasing an additional 1,179,830 shares during the period. Acadian Asset Management LLC boosted its holdings in Amneal Pharmaceuticals by 701.
8% during the second quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock worth $5,148,000 after buying an additional 710,598 shares during the last quarter. Assenagon Asset Management S.
A. grew its position in shares of Amneal Pharmaceuticals by 114.1% during the 3rd quarter.
Assenagon Asset Management S.A. now owns 1,204,994 shares of the company’s stock worth $10,026,000 after buying an additional 642,065 shares during the period.
Dimensional Fund Advisors LP increased its stake in shares of Amneal Pharmaceuticals by 17.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock valued at $27,205,000 after acquiring an additional 641,405 shares during the last quarter.
Finally, BlackBarn Capital Partners LP raised its position in shares of Amneal Pharmaceuticals by 41.5% in the 2nd quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock valued at $12,700,000 after acquiring an additional 586,703 shares during the period.
Institutional investors and hedge funds own 31.82% of the company’s stock. About Amneal Pharmaceuticals ( Get Free Report ) Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. See Also Five stocks we like better than Amneal Pharmaceuticals Low PE Growth Stocks: Unlocking Investment Opportunities Opal Fuels CEO on Steering the Future of Renewable Natural Gas How to Invest in Blue Chip Stocks MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win What Makes a Stock a Good Dividend Stock? 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
